Mikhail Blagosklonny Presses for the Health Benefits of Rapamycin, Including its Anti-aging Properties

Mikhail Blagosklonny, a leading oncology and anti-aging researcher, explained the health benefits of Rapamycin, including its anti-aging properties. He confirms that Rapamycin is the medicine of future, and further research on its benefits can bring more incredible results. It was isolated from a bacterium named Sirolimus in 1972 and initially, used as an anti-fungal agent. Later, it was also started using as a drug to treat the organ transplant rejection found in the humans. In the later years, Mikhail Blagosklonny started researching on the benefits of the drug and found that it can produce wonders in the human body with many healthcare benefits.Blagosklonny identified that Rapamycin could be administered effectively to increase the lifespan in human beings. He says that it can be used to treat people struggling with hemolytic-uremic syndrome – a rare disease that includes kidney failure, low platelet count, and anemia. In such health conditions, kidney transplantation is the only solution, and Rapamycin would ensure smooth acceptance of the external organ into the human body. Additionally, it also showcases lower rate of toxicity towards kidneys.

It is also an effective drug in treating Lymphangioleiomyomatosis – a rare lung disease that is observed in women while they are pregnant. The drug is also identified as an option of cancer treatment for Facial angiofibromas, and Rapamycin is found to be producing better results than laser treatment option. Rapamycin is also effective in the coating of coronary stents. The coating is to prevent the possibilities of re-stenosis in the arteries due to balloon angioplasty. Blagosklonny also says that the drug is effective in cancer treatment as its antiproliferative properties play a major role in increasing immunity. It is proved that when taken in the right dose, the drug has the ability to increase the immune response towards cancerous cells. Additionally, it also promotes tumor regression and works as a preventive option to reduce the risk of cancer. It is also identified that the drug can be used for the treatment of Tuberous Sclerosis Complex, a congenital disorder which can cause tumor growth in kidneys, heart, brain, and other organs.

Blagosklonny further says that it can also provide significant results in Alzheimer’s disease and Muscular Dystrophy.Mikhail Blagosklonny is also a  great philanthropist and professor with a vision of developing efficient treatment solutions that are accessible by anyone, irrespective of the financial conditions. He is considered as a towering figure in both anti-aging research and oncology, and researchers around the world demand his guidance in both the areas. Through cancer research, Blagosklonny is looking for a cancer treatment option that can ensure killing of cancerous cells without damaging the healthy cells of the human body – an important factor in deciding the recovery of the patient.Blagosklonny has made significant progress in both anti-aging research and cancer treatment in the recent years. He has published over 300 research papers, notes, reviews, and more. Blagosklonny has collaborated with a number of science and medical journals and worked on their editorial boards in different roles. Currently, he is working as a researcher at Rosewell Park Cancer Institute.

Eric Lefkofsky- The World’s Hope For Curing Cancer

Eric Lefkofsky and his partner Brad Keywell have been involved in turning startups into prosperous companies. The duo has made a name for itself as among the most resourceful technological team in Chicago.

The Establishment of Tempus

Everything changed for Lefkofsky when his wife was diagnosed with cancer. According to Lefkofsky, many people experience reaction after a cancer diagnosis. Many people diagnosed with cancer act confused, are not sure what they are dealing with, and cannot believe that the information is so limited.

Lefkofsky and Keywell established Tempus, a data driven strategy to treat cancer. Tempus employs the use of genomic sequencing and machine learning to get a better understanding of the tumor in a patient. After examining the tumor in a patient, Tempus employs a treatment plan that will help combat the tumor.

Lefkofsky stated in an interview that Tempus was the beginning of a technology shift in the healthcare sector. Lefkofsky has compared Tempus to social sites that changed the internet experience namely; Face book and Google.

Lefkofsky, according to data from Forbes, is worth $1.7 billion. The man is determined to invest hundreds of millions of his fortune into Tempus so that it remains self-funded. This will give Tempus an edge over other companies that rely on donors to remain afloat to learn more: http://investor.groupon.com/directors.cfm click here.

About Eric Lefkofsky

Lefkofsky is the CEO and co-founder of Tempus, a tech company established to wage war on cancer. He is also a co-founder of Lightbank, an initiative that invests in disruptive technologies. Lefkofsky is also the chairman and co-founder of Groupon, an e-commerce marketplace. Lefkofsky also co-founded Uptake Technologies, one of the most recognized predictive analytics center for global industries: Echo Global Logistics, Mediaocean, and InnerWorkings.

In 2006, Lefkofsky, flanked by his wife Liz, created the “Lefkofsky Family Foundation”, a charity meant to promote high-impact initiatives that improve lives. Lefkofsky is also a Trustee of “The Art Institute of Chicago”, “The Lurie Children’s Hospital” (Chicago), and ” Science, Industry, and World Business Museum”(Chicago). He is an adjunct professor and also the author of Accelerated Disruption. Lefkofsky graduated from the “University of Michigan” and acquired his Juris Doctor from the “University of Michigan” Law School.